ReviewOncology research2026
Targeting Cytoskeleton and Cell Motility: Past and Novel Strategies for Cancer Therapy.
Review in Oncology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cytoskeletal reorganization is fundamental to essential cellular processes, including shape maintenance, migration, adhesion cytokinesis, and phagocytosis, and its dysregulation is a hallmark of tumor progression. In cancer cells, altered cytoskeletal dynamics promote invasion and genomic instability resulting from mitotic defects. The actin and microtubule cytoskeletons are highly dynamic polymer networks that organize intracellular architecture, establish polarity, and generate the mechanical forces required for cell division and motility. Their dysregulation disrupts normal cell behavior and facilitates tumor invasion and metastasis. The cytoskeleton therefore represents a key source of potential therapeutic targets for inhibiting metastatic dissemination. This review focuses on recent anticancer strategies targeting cytoskeletal and motility-associated pathways, including microtubule-directed agents, actin-modulating compounds, inhibitors of focal adhesion signaling, modulators of intermediate filament dynamics, and regulators of cytoskeletal crosstalk. Collectively, these strategies underscore the central role of cytoskeleton in cancer progression and highlight its potential as a promising therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.